Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]RIST4721 in Healthy Males
NCT05023811Phase 1Completed
- Sponsor
- Aristea Therapeutics
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vimnerixin in palmoplantar pustulosis (PPP), sponsored by Aristea Therapeutics. Primary endpoints: Mass balance recovery of total radioactivity in all excreta: CumAe, Mass balance recovery of total radioactivity in all excreta: Cum%Ae and 3 more. Started Aug 2021; status: completed.
02
Drugs
vimnerixin
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT05023811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023811.